For the quarter ending 2025-12-31.
| Income Statement | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|
| Revenue | 0 | 3 | 3 | 122 |
| Cost of revenue | 0 | - | 1 | 25 |
| Gross profit | 0 | - | 3 | 97 |
| General and administrative expenses | 470 | 245 | 214 | 283 |
| Research and development expenses | 4 | 7 | 19 | 42 |
| Total operating expenses | 474 | 252 | 233 | 325 |
| Loss from operations | -474 | -249 | -230 | -228 |
| Gain on patent assignment | 0 | - | 0 | - |
| Interest expense | 2 | 9 | 1 | 2 |
| Net income (loss) | -476 | -258 | -231 | -230 |
| Net income (loss) per share, basic | 0 | 0 | 0 | 0 |
| Net income (loss) per share, diluted | 0 | 0 | 0 | 0 |
| Weighted average shares outstanding, basic | 301,177,864 | 289,156,340 | -142,378,048 | 286,467,487 |
| Weighted average shares outstanding, diluted | 301,177,864 | 289,156,340 | -142,378,048 | 286,467,487 |
Cavitation Technologies, Inc. (CVAT)
Cavitation Technologies, Inc. (CVAT)